A Double-blind, Randomized, Placebo Controlled, 4-week Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female Participants
Latest Information Update: 22 Jul 2021
At a glance
- Drugs Aticaprant (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 19 Jul 2021 Status changed from recruiting to completed.
- 14 Apr 2021 Planned primary completion date changed from 30 Jul 2020 to 22 Apr 2021.
- 04 Feb 2021 Planned End Date changed from 30 Mar 2021 to 17 May 2021.